FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204978082> ?p ?o ?g. }

• W3204978082 abstract "<h3>Introduction/Background*</h3> There is no standard of care regimen in the second-line setting for women with recurrent/metastatic (R/M) cervical carcinoma. Cemiplimab was recently shown to significantly improve overall survival (OS) compared with investigator’s choice (IC) chemotherapy in patients with R/M cervical cancer after first-line platinum-based chemotherapy (NCT03257267; ESMO-VP-2021). We present a pre-planned exploratory subgroup analysis comparing cemiplimab to individual IC chemotherapy options. <h3>Methodology</h3> EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 is an open-label, randomised (1:1), multi-centre, Phase 3 clinical trial of anti-programmed cell death (PD)-1 cemiplimab vs IC single agent chemotherapy in R/M cervical cancer that has progressed after first-line platinum-based treatment. The selection of single-agent chemotherapy by the investigator (gemcitabine, pemetrexed, vinorelbine, topotecan or irinotecan) was not protocol-defined, but the regimen had to be chosen prior to randomisation. Adult females (age ≥18 years) were enrolled regardless of PD-ligand 1 expression and received cemiplimab 350 mg intravenously every 3 weeks or IC chemotherapy for up to 96 weeks; and were stratified by histology (squamous cell carcinoma/adenocarcinoma or adenosquamous), geographic region (North America/Asia/rest of world), prior bevacizumab, and ECOG performance status (0/1). Primary endpoint was OS. Additional endpoints included progression-free survival (PFS), objective response rate (ORR), duration of response, quality of life and safety. Data cutoff was 4 January 2021. <h3>Result(s)*</h3> A total of 608 patients were randomised: 304 to cemiplimab and 304 to IC chemotherapy (gemcitabine, n=121; premetrexed, n=111; vinorelbine, n=32; topotecan, n=21; irinotecan, n=19) across geographic regions and histologies. Median duration of study follow-up (range) was 4.8 months (0.0–25.9) for the overall population. At second interim analysis, the trial was stopped early for efficacy. OS, PFS and ORR (table 1) demonstrated improvements with cemiplimab vs each IC chemotherapy treatment similar to those observed with cemiplimab vs pooled IC chemotherapy. <h3>Conclusion*</h3> Improvements in OS, PFS and ORR with cemiplimab trended consistently with the results for the overall population regardless of IC chemotherapy drug." @default.
• W3204978082 created "2021-10-25" @default.
• W3204978082 creator A5000448920 @default.
• W3204978082 creator A5006919842 @default.
• W3204978082 creator A5009690244 @default.
• W3204978082 creator A5014087330 @default.
• W3204978082 creator A5014699289 @default.
• W3204978082 creator A5018910129 @default.
• W3204978082 creator A5026335885 @default.
• W3204978082 creator A5027362680 @default.
• W3204978082 creator A5030810607 @default.
• W3204978082 creator A5037707645 @default.
• W3204978082 creator A5044041188 @default.
• W3204978082 creator A5050850130 @default.
• W3204978082 creator A5058535647 @default.
• W3204978082 creator A5060469120 @default.
• W3204978082 creator A5061939825 @default.
• W3204978082 creator A5065325837 @default.
• W3204978082 creator A5067053417 @default.
• W3204978082 creator A5069655013 @default.
• W3204978082 creator A5077024316 @default.
• W3204978082 creator A5091843646 @default.
• W3204978082 date "2021-10-01" @default.
• W3204978082 modified "2023-10-01" @default.
• W3204978082 title "164 Phase 3 recurrent/metastatic cervical carcinoma trial: subgroup efficacy analysis of cemiplimab versus individual investigator’s choice chemotherapy" @default.
• W3204978082 doi "https://doi.org/10.1136/ijgc-2021-esgo.14" @default.
• W3204978082 hasPublicationYear "2021" @default.
• W3204978082 type Work @default.
• W3204978082 sameAs 3204978082 @default.
• W3204978082 citedByCount "0" @default.
• W3204978082 crossrefType "proceedings-article" @default.
• W3204978082 hasAuthorship W3204978082A5000448920 @default.
• W3204978082 hasAuthorship W3204978082A5006919842 @default.
• W3204978082 hasAuthorship W3204978082A5009690244 @default.
• W3204978082 hasAuthorship W3204978082A5014087330 @default.
• W3204978082 hasAuthorship W3204978082A5014699289 @default.
• W3204978082 hasAuthorship W3204978082A5018910129 @default.
• W3204978082 hasAuthorship W3204978082A5026335885 @default.
• W3204978082 hasAuthorship W3204978082A5027362680 @default.
• W3204978082 hasAuthorship W3204978082A5030810607 @default.
• W3204978082 hasAuthorship W3204978082A5037707645 @default.
• W3204978082 hasAuthorship W3204978082A5044041188 @default.
• W3204978082 hasAuthorship W3204978082A5050850130 @default.
• W3204978082 hasAuthorship W3204978082A5058535647 @default.
• W3204978082 hasAuthorship W3204978082A5060469120 @default.
• W3204978082 hasAuthorship W3204978082A5061939825 @default.
• W3204978082 hasAuthorship W3204978082A5065325837 @default.
• W3204978082 hasAuthorship W3204978082A5067053417 @default.
• W3204978082 hasAuthorship W3204978082A5069655013 @default.
• W3204978082 hasAuthorship W3204978082A5077024316 @default.
• W3204978082 hasAuthorship W3204978082A5091843646 @default.
• W3204978082 hasBestOaLocation W32049780821 @default.
• W3204978082 hasConcept C126322002 @default.
• W3204978082 hasConcept C143998085 @default.
• W3204978082 hasConcept C203092338 @default.
• W3204978082 hasConcept C2776694085 @default.
• W3204978082 hasConcept C2778239845 @default.
• W3204978082 hasConcept C2778336483 @default.
• W3204978082 hasConcept C2780258809 @default.
• W3204978082 hasConcept C2780350996 @default.
• W3204978082 hasConcept C2781413609 @default.
• W3204978082 hasConcept C535046627 @default.
• W3204978082 hasConcept C71924100 @default.
• W3204978082 hasConceptScore W3204978082C126322002 @default.
• W3204978082 hasConceptScore W3204978082C143998085 @default.
• W3204978082 hasConceptScore W3204978082C203092338 @default.
• W3204978082 hasConceptScore W3204978082C2776694085 @default.
• W3204978082 hasConceptScore W3204978082C2778239845 @default.
• W3204978082 hasConceptScore W3204978082C2778336483 @default.
• W3204978082 hasConceptScore W3204978082C2780258809 @default.
• W3204978082 hasConceptScore W3204978082C2780350996 @default.
• W3204978082 hasConceptScore W3204978082C2781413609 @default.
• W3204978082 hasConceptScore W3204978082C535046627 @default.
• W3204978082 hasConceptScore W3204978082C71924100 @default.
• W3204978082 hasLocation W32049780821 @default.
• W3204978082 hasOpenAccess W3204978082 @default.
• W3204978082 hasPrimaryLocation W32049780821 @default.
• W3204978082 hasRelatedWork W1550216372 @default.
• W3204978082 hasRelatedWork W2073104701 @default.
• W3204978082 hasRelatedWork W2078127843 @default.
• W3204978082 hasRelatedWork W2085142786 @default.
• W3204978082 hasRelatedWork W2351131972 @default.
• W3204978082 hasRelatedWork W2362844636 @default.
• W3204978082 hasRelatedWork W2402259451 @default.
• W3204978082 hasRelatedWork W2439707001 @default.
• W3204978082 hasRelatedWork W2468005262 @default.
• W3204978082 hasRelatedWork W2621339296 @default.
• W3204978082 isParatext "false" @default.
• W3204978082 isRetracted "false" @default.
• W3204978082 magId "3204978082" @default.
• W3204978082 workType "article" @default.